[Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma].

OBJECTIVE

To explore the potential mechanism of resistance to axitinib in clear cell renal cell carcinoma (ccRCC), with a view to expanding the understanding of axitinib resistance, facilitating the design of more specific treatment options, and improving the treatment effectiveness and survival prognosis of patients.

METHODS

By exploring the half maximum inhibitory concentration (IC) of axitinib on ccRCC cell lines 786-O and Caki-1, cell lines resistant to axitinib were constructed by repeatedly stimulated with axitinib at this concentration for 30 cycles . Cell lines that were not treated by axitinib were sensitive cell lines. The phenotypic differences of cell proliferation and apoptosis levels between drug resistant and sensitive lines were tested. Genes that might be involved in the drug resistance process were screened from the differentially expressed genes that were co-upregulated in the two drug resistant lines by transcriptome sequencing. The expression level of the target gene in the drug resistant lines was verified by real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot (WB). The expression differences of the target gene in ccRCC tumor tissues and adjacent tissues were analyzed in the Gene Expression Profiling Interactive Analysis (GEPIA) public database, and the impact of the target gene on the prognosis of ccRCC patients was analyzed in the Kaplan-Meier Plotter (K-M Plotter) database. After knocking down the target gene in the drug resistant lines using RNA interference by lentivirus vector, the phenotypic differences of the cell lines were tested again. WB was used to detect the levels of apoptosis-related proteins in the different treated cell lines to find molecular pathways that might lead to drug resistance.

RESULTS

Cell lines 786-O-R and Caki-1-R resistant to axitinib were successfully constructed , and their IC were significantly higher than those of the sensitive cell lines (10.99 μmol/L, < 0.01; 11.96 μmol/L, < 0.01, respectively). Cell counting kit-8 (CCK-8) assay, colony formation, and 5-ethynyl-2 '-deoxyuridine (EdU) assay showed that compared with the sensitive lines, the proliferative ability of the resistant lines decreased, but apoptosis staining showed a significant decrease in the level of cell apoptosis of the resistant lines ( < 0.01). Although resistant to axitinib, the resistant lines had no obvious new replicated cells in the environment of 20 μmol/L axitinib. Nuclear protein 1 () gene was screened by transcriptome sequencing, and its RNA ( < 0.0001) and protein expression levels significantly increased in the resistant lines. Database analysis showed that was significantly overexpressed in ccRCC tumor tissue ( < 0.05); the ccRCC patients with higher expression ofhad a worse survival prognosis ( < 0.001). Apoptosis staining results showed that knockdown ofinhibited the anti-apoptotic ability of the resistant lines to axitinib (786-O, < 0.01; Caki-1, < 0.05). WB results showed that knocking downdecreased the protein level of B-cell lymphoma-2 (BCL2), increased the protein level of BCL2-associated X protein (BAX), decreased the protein level of pro-caspase3, and increased the level of cleaved-caspase3 in the resistant lines after being treated with axitinib.

CONCLUSION

ccRCC cell lines reduce apoptosis through the -/ -caspase3 pathway, which is involved in the process of resistance to axitinib.